211 related articles for article (PubMed ID: 31694094)
21. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.
Maltais F; Hamilton A; Voß F; Maleki-Yazdi MR
Adv Ther; 2019 Apr; 36(4):962-968. PubMed ID: 30843141
[TBL] [Abstract][Full Text] [Related]
22. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.
Singh D; Gaga M; Schmidt O; Bjermer L; Grönke L; Voß F; Ferguson GT
Respir Res; 2016 Jun; 17(1):73. PubMed ID: 27316465
[TBL] [Abstract][Full Text] [Related]
23. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Koch A; Pizzichini E; Hamilton A; Hart L; Korducki L; De Salvo MC; Paggiaro P
Int J Chron Obstruct Pulmon Dis; 2014; 9():697-714. PubMed ID: 25045258
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis.
Miravitlles M; Urrutia G; Mathioudakis AG; Ancochea J
Respir Res; 2017 Nov; 18(1):196. PubMed ID: 29178871
[TBL] [Abstract][Full Text] [Related]
25. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
26. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.
Maltais F; O'Donnell D; Gáldiz Iturri JB; Kirsten AM; Singh D; Hamilton A; Tetzlaff K; Zhao Y; Casaburi R
Ther Adv Respir Dis; 2018; 12():1753465818755091. PubMed ID: 29439648
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
van Boven JF; Kocks JW; Postma MJ
Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and safety of tiotropium+olodaterol 5 μg/5 μg fixed-dose combination in Chinese patients with COPD.
Wang Z; Tadayasu Y; Hu N; Shu S; Hu C; Luo Z
Pulm Pharmacol Ther; 2020 Aug; 63():101944. PubMed ID: 32916296
[TBL] [Abstract][Full Text] [Related]
29. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety and efficacy of combined tiotropium and olodaterol in Japanese patients with chronic obstructive pulmonary disease.
Ichinose M; Kato M; Takizawa A; Sakamoto W; Grönke L; Tetzlaff K; Fukuchi Y
Respir Investig; 2017 Mar; 55(2):121-129. PubMed ID: 28274527
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD.
Derom E; Brusselle GG; Joos GF
Int J Chron Obstruct Pulmon Dis; 2016; 11():3163-3177. PubMed ID: 28008243
[TBL] [Abstract][Full Text] [Related]
32. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Farne HA; Cates CJ
Cochrane Database Syst Rev; 2015 Oct; (10):CD008989. PubMed ID: 26490945
[TBL] [Abstract][Full Text] [Related]
33. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Calverley PMA; Anzueto AR; Carter K; Grönke L; Hallmann C; Jenkins C; Wedzicha J; Rabe KF
Lancet Respir Med; 2018 May; 6(5):337-344. PubMed ID: 29605624
[TBL] [Abstract][Full Text] [Related]
34. COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy.
Calverley PMA; Hoz A; Xue W; Ferguson GT; Miravitlles M
COPD; 2020 Oct; 17(5):477-484. PubMed ID: 32928003
[TBL] [Abstract][Full Text] [Related]
35. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.
Ferguson GT; Feldman GJ; Hofbauer P; Hamilton A; Allen L; Korducki L; Sachs P
Int J Chron Obstruct Pulmon Dis; 2014; 9():629-45. PubMed ID: 24966672
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of the long-acting β2-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease.
Ichinose M; Takizawa A; Izumoto T; Tadayasu Y; Hamilton AL; Kunz C; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():1673-83. PubMed ID: 26316741
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
Ichinose M; Minakata Y; Motegi T; Ueki J; Gon Y; Seki T; Anzai T; Nakamura S; Hirata K
Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
[TBL] [Abstract][Full Text] [Related]
39. [The efficacy and safety of low-dose tiotropium bromide inhaled via Respimat® in patients with chronic obstructive pulmonary disease].
Ma J; Zhou Z; Tang Y; Zhong N
Zhonghua Nei Ke Za Zhi; 2014 Dec; 53(12):964-8. PubMed ID: 25623564
[TBL] [Abstract][Full Text] [Related]
40. Tiotropium/Olodaterol: A Review in COPD.
Blair HA
Drugs; 2019 Jun; 79(9):997-1008. PubMed ID: 31119643
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
